Author name: SpicyIP

Following the concerns raised over allegations of lack of uniform standards of the Indian Patent Office in part I of this post series, this post attempts to put forth details of the various patent applications made by Indian companies (claiming patent for variants of imatinib mesylate). The aim is to get readers familiar with this area to comment on the possible outcome of these applications given the rigorous Section 3(d) standards as introduced applied in the Novartis case. To reiterate, […]

In an article titled “India rejects Patent to Glivec’s Second Variant,” the Business Standard reported that the Swiss drug manufacturing multinational, Novartis AG, had been dealt with another blow by the Indian Patent Office. The Patent Office, in its March 30 ruling, accepted the pre-grant oppositions filed by Indian drug firms Sun Pharma, Okasa and others against Novartis’s five-year-old patent application over the alpha crystal form of Novartis’s blockbuster cancer medicine, Glivec. This setback follows the steps of the erstwhile

WIPO (World Intellectual Property Organisation) is a specialized agency of the United Nations, dedicated to developing a balanced and accessible international intellectual property (IP) system. The WIPO Magazine, a bimonthly Magazine issued by WIPO (isn’t that a guess!) aims to inform readers about WIPO-led activities, and to show intellectual property, creativity and innovation at work across the world. Thus, the magazine features selected initiatives, policies, meetings, and other activities that have an impact WIPO’s work and the work of the

I would like to thank Question IPR for his/her comments on Part I of the post series and am reproducing the his/her first comment below for a better understanding of the law of secondary liability for copyright infringement in the U.S. Question IPR stated that, “Indirect infringement liability (Secondary liability for Copyright infringement) in the United States can be divided into three major headings as of today: · Contributory Infringement · Vicarious Infringement · Inducement standard [I disagree with him/her.